OTHER INFORMATION.
+Added: the six months ended June 30, 2024, none of the Company’s directors or officers adopted or terminated any contract, instruction
+Added: or written plan for the purchase or sale of the Company’s securities that was intended to satisfy the affirmative defense conditions
+Added: of Rule 10b5–1(c) or any “non-Rule 10b5-1 trading arrangement” (as such terms are defined in Item 408 of Regulation
+Added: S-K of the Securities Act).
the Exhibit Index following the signature page to this Quarterly Report on Form 10-Q for a list of exhibits filed or furnished with this
3 unchanged sentences
BIOPHARMA HOLDINGS, INC.
+Added: August 14, 2024
Executive Officer (Principal Executive Officer)
+Added: August 14, 2024
Financial Officer
7 unchanged sentences
Common Stock Purchase Warrant, dated April 5, 2024 (incorporated herein by reference to the Company’s Current Report on Form 8-K filed with the SEC on April 5, 2024).
−Removed: Description of Securities.
Securities Purchase Agreement, dated April 2, 2024 (incorporated herein by reference to the Company’s Current Report on Form 8-K filed with the SEC on April 5, 2024).
15 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.